“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that ...

Recent advances in artificial intelligence (AI) have generated a tsunami of popular dystopian musings, but the U.S. Patent ...

Australia is poised to play a leading role in the rise of the global radiopharmaceutical industry, as advanced therapies ...

In the wake of Novo Nordisk’s semaglutide nabbing the title of the U.S.’s biggest blockbuster drug, it’s little surprise that ...

Latus Bio Inc. has launched with a focus on developing novel gene therapy candidates for central nervous system (CNS) ...

Hologic Inc. moved to expand its breast surgery line with the acquisition of Endomagnetics Ltd. (Endomag) for a proposed $310 ...

Medtronic plc said it secured U.S. FDA approval for its first closed-loop spinal cord stimulator (SCS), designed to take in ...

Kurome Therapeutics Inc. along with the Cincinnati Children’s Hospital Medical Center and U.S. Department of Health and Human Services have patented interleukin-1 receptor-associated kinase (IRAK) and ...

Obesity candidate Maritide (maridebart cafraglutide) took center stage during Amgen Inc.’s first-quarter earnings call after market close May 2, with company executives touting early phase II data and ...

Context Therapeutics Inc. has received FDA clearance of its IND application for CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.

Shares of Aeon Biopharma Inc. (NYSE:AEON) closed May 3 down $1.66, or 49%, finishing at $1.70 on word that the planned interim analysis of phase II data with ABP-450 (prabotulinumtoxinA) for ...

Philadelphia-based Latus Bio Inc., co-founded by serial biotech entrepreneurs P. Peter Ghoroghchian and Beverly Davidson, launched on May 2 with two lead adeno-associated virus (AAV)-based gene ...